To the Editor We read with interest the study of Hank et al,1 which proposes that there is a decreased risk of developing clinically relevant pancreatic fistula (CR-POPF) when neoadjuvant chemotherapy (NAT) therapy is applied for pancreatic adenocarcinoma. They suggest induction of fibrosis of the pancreatic gland as a proposed mechanism. While the data appear intriguing, there are some methodologic issues that raise questions.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Trudeau MT, Vollmer CM. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy. JAMA Surg. 2020;155(3):268–269. doi:10.1001/jamasurg.2019.5090
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: